Toxoplasmosis in Humans and Cats: Zoonotic Risks and Public Health Implications

Introduction

Toxoplasmosis is a globally distributed zoonotic disease caused by the obligate intracellular apicomplexan parasite Toxoplasma gondii. The definitive hosts for T. gondii are members of the family Felidae, including domestic cats (Felis catus), in which the parasite completes its sexual life cycle and produces environmentally resistant oocysts [1, 2]. All warm-blooded vertebrates, including humans, can serve as intermediate hosts, harboring the parasite in its asexual stages [3, 4]. The public health significance of toxoplasmosis is substantial, given its potential to cause severe disease in immunocompromised individuals and congenitally infected neonates [5, 6, 7]. This article provides a detailed veterinary and public health review of T. gondii infection, focusing on the parasite's biology, transmission dynamics, clinical manifestations in definitive and intermediate hosts, diagnostic approaches, and preventive strategies. A specific focus is placed on addressing common misconceptions, including the colloquial association of toxoplasmosis with the "toxoplasmosis cat lady disease" stereotype, which conflates cat ownership with irrational risk perception [8].

Parasite Lifecycle and Biology

The lifecycle of T. gondii is complex, involving both sexual and asexual replication phases. Sexual reproduction occurs exclusively within the intestinal epithelium of felids, leading to the production of unsporulated oocysts that are shed in feces [9, 1]. A single infected cat can shed millions of oocysts over a period of one to three weeks [2, 10]. After shedding, oocysts sporulate in the environment within one to five days, becoming infectious to intermediate hosts [11, 2]. Sporulated oocysts are highly resilient and can remain viable in soil, water, and on surfaces for months to years [11, 12].

Upon ingestion by an intermediate host, sporozoites are released from oocysts and differentiate into tachyzoites, the rapidly replicating form responsible for acute infection [13]. Tachyzoites disseminate throughout the host via the bloodstream and lymphatic system, invading nucleated cells of multiple tissues [13]. In response to host immune pressure, tachyzoites convert to bradyzoites, which form tissue cysts predominantly in the brain, skeletal muscle, and myocardium [14, 15]. These cysts persist for the lifetime of the host and represent a source of latent infection [14]. The pre-sexual stages of the parasite in the feline gut have been characterized at the single-cell level, revealing distinct transcriptional programs that drive the transition from asexual to sexual development [9, 1]. Recent advances using retinal epithelial cells and intestinal organoids have enabled the in vitro differentiation of pre-sexual and sexual stages, providing a powerful tool for studying this critical phase of the lifecycle [16].

Transmission Routes

Transmission of T. gondii to humans and other intermediate hosts occurs via three primary routes: oral ingestion, congenital transmission, and iatrogenic transmission.

Oral Ingestion

Oral ingestion is the most common route of infection. This occurs through the consumption of undercooked or raw meat containing tissue cysts, particularly from pigs, sheep, and goats [3, 17]. Ingestion of food or water contaminated with sporulated oocysts from feline feces is another major source [11, 12]. Oocysts can contaminate vegetables, fruits, and water sources, and are resistant to standard water treatment processes [11, 12]. The survival of tachyzoites in cow's milk has been demonstrated, with viability dependent on temperature, suggesting a potential but less common route of transmission [17].

Congenital Transmission

Congenital toxoplasmosis occurs when a pregnant female acquires a primary T. gondii infection during gestation. Tachyzoites cross the placental barrier and infect the fetus, potentially leading to miscarriage, stillbirth, or severe neonatal disease [18, 6, 19, 7]. The risk and severity of fetal infection depend on the gestational stage at which maternal infection occurs, with first-trimester infections associated with more severe outcomes [7]. Seroprevalence studies in women with a history of abortion or stillbirth have identified T. gondii seropositivity as a significant associated factor [18]. In Burundi, the burden of congenital toxoplasmosis has been assessed, highlighting the need for surveillance in endemic regions [6].

Iatrogenic Transmission

Iatrogenic transmission can occur through blood transfusion or organ transplantation from an infected donor [20, 5]. T. gondii seropositivity has been associated with blood transfusion history in patients with sickle cell disease [20]. Cerebral toxoplasmosis is a recognized complication in renal transplant recipients, typically resulting from reactivation of latent infection in the recipient or transmission from a seropositive donor [5].

Clinical Signs in Cats

Most immunocompetent cats infected with T. gondii remain asymptomatic [21, 2, 22]. When clinical signs do occur, they are most commonly observed in kittens or immunocompromised adults. Clinical toxoplasmosis in cats can manifest as a multisystemic disease, with the most frequently reported signs including fever, lethargy, anorexia, and lymphadenopathy [23]. Ocular disease, such as uveitis and chorioretinitis, is also observed [24]. Neurological signs, including ataxia, seizures, and behavioral changes, can result from encephalitis [23]. Respiratory signs, such as dyspnea and tachypnea, may occur due to pneumonia [23]. Hepatic and pancreatic involvement can lead to icterus and vomiting [23]. A case report described a mouse-virulent recombinant type I/III T. gondii strain identified in the liver cytology of an immunosuppressed cat co-infected with feline leukemia virus (FeLV), demonstrating the potential for severe disease in co-infected animals [23].

Clinical Signs in Humans

In immunocompetent humans, primary T. gondii infection is typically asymptomatic or presents as a mild, self-limiting febrile illness with lymphadenopathy [15]. However, the parasite can cause significant disease in specific populations.

Ocular Toxoplasmosis

Ocular toxoplasmosis is a leading cause of posterior uveitis worldwide [25, 15]. It can result from congenital infection or, more commonly, from acquired infection. The characteristic lesion is a focal necrotizing retinochoroiditis, which can lead to vision loss if the macula or optic nerve is involved [25]. Reactivation of latent retinal cysts can cause recurrent episodes of inflammation [25].

Toxoplasmosis in Immunocompromised Individuals

In immunocompromised individuals, such as those with HIV/AIDS, organ transplant recipients, or patients undergoing immunosuppressive therapy, reactivation of latent T. gondii infection can cause severe, life-threatening disease [5, 26]. The most common manifestation is cerebral toxoplasmosis, presenting with headache, confusion, seizures, and focal neurological deficits [5]. Other manifestations include pneumonitis, myocarditis, and disseminated disease [26]. Seroprevalence studies in patients with malignancies have shown a higher risk of infection in this population [26].

Congenital Toxoplasmosis

Congenital toxoplasmosis can result in a spectrum of outcomes, from asymptomatic infection to severe disease [18, 6, 7]. Classic manifestations include intracranial calcifications, hydrocephalus, and chorioretinitis [7]. Long-term sequelae can include visual impairment, hearing loss, and neurodevelopmental delays [7].

Diagnosis

Diagnosis of T. gondii infection relies on a combination of serological, molecular, and histopathological methods.

Serological Diagnosis

Serological detection of anti-T. gondii antibodies (IgG and IgM) is the most common diagnostic approach in both humans and animals [27, 28, 29, 21, 2, 22]. In cats, seroprevalence studies have been conducted globally, with rates varying widely depending on geographic location, lifestyle (indoor vs. outdoor), and population (client-owned vs. stray) [21, 2, 12, 22]. In Hong Kong, seroprevalence in privately-owned cats and community cats was found to be associated with demographic factors [21]. In Kazakhstan, urban client-owned cats showed a seroprevalence of 18.5% [22]. In Jordan, the first seroprevalence and molecular detection study in cats reported a seroprevalence of 31.4% [2]. In Brazil, high seroprevalence rates have been documented in dogs and cats in urban informal settlements [12].

Rapid diagnostic tests, such as colloidal gold immunochromatographic strips, have been developed for the detection of T. gondii antibodies in multiple host species, including swine and cats [27, 29]. These assays offer a rapid, field-deployable alternative to traditional laboratory-based serological methods [27, 29]. A double-antigen sandwich format has been validated for use in multiple species, enhancing its utility in veterinary practice [27]. The SAG1 antigen has been used as a target for serological detection in swine [29]. The MIC17A antigen has shown potential as a marker for both entero-epithelial and chronic stage infection in cats [24].

Molecular Diagnosis

Polymerase chain reaction (PCR) assays are used for the direct detection of T. gondii DNA in clinical samples, including blood, cerebrospinal fluid, aqueous humor, and tissues [11, 2, 30]. PCR is particularly useful for diagnosing active infection and for genotyping the parasite [11, 23]. An antisense PCR assay has been developed and evaluated for T. gondii detection in domestic cats, offering improved sensitivity [30]. PCR detection of T. gondii DNA in fecal samples from stray cats has been used to assess environmental contamination risk [11].

Histopathological and Cytological Diagnosis

Histopathological examination of tissues, such as brain, liver, and lung, can reveal the presence of tachyzoites or tissue cysts [23]. Immunohistochemistry can be used to confirm the identity of the parasite [23]. Cytological examination of aspirates or impression smears can also be diagnostic in some cases [23].

Treatment

Treatment for clinical toxoplasmosis in cats typically involves a combination of clindamycin, which is the drug of choice, and supportive care [23]. In humans, the standard treatment for active toxoplasmosis is a combination of pyrimethamine and sulfadiazine, supplemented with folinic acid to reduce hematologic toxicity [5, 7]. Treatment is indicated for immunocompromised patients with active disease, for pregnant women with acute infection to prevent congenital transmission, and for infants with congenital toxoplasmosis [7].

Prevention and Public Health Implications

Prevention of T. gondii infection requires a multi-faceted approach targeting both feline and human populations.

Feline Management

Preventing oocyst shedding in cats is a key public health goal. This can be achieved by feeding cats only cooked or commercially processed food, preventing them from hunting, and keeping them indoors [8, 31]. Daily cleaning of litter boxes, ideally by a non-pregnant, immunocompetent individual, and proper disposal of cat feces are essential [8]. Vaccination of cats against T. gondii is an area of active research. A recombinant GRA12 vaccine has shown immunogenicity and protective efficacy in domestic cats, reducing oocyst shedding [31]. An inactivated vaccine has also been evaluated for its impact on toxoplasmosis-associated mortality in captive wildlife [32].

Human Prevention

Human prevention strategies focus on food safety and hygiene. These include cooking meat to safe internal temperatures, washing fruits and vegetables thoroughly, and practicing good hand hygiene after handling raw meat or soil [8, 17]. Pregnant women and immunocompromised individuals should take particular care to avoid exposure to cat feces and undercooked meat [8, 7]. The association between childhood T. gondii infection and psychotic experiences has been investigated, highlighting the potential long-term neuropsychiatric implications of infection [14].

Addressing the "Toxoplasmosis Cat Lady Disease" Misconception

The colloquial term "toxoplasmosis cat lady disease" perpetuates a misleading and stigmatizing association between cat ownership and irrational behavior. While T. gondii infection can influence behavior in rodents, evidence for similar effects in humans is inconsistent and methodologically contested [14, 8]. The primary risk factors for human infection are consumption of undercooked meat and poor hygiene, not simply living with a cat [8]. Responsible cat ownership, including keeping cats indoors and feeding them a commercial diet, dramatically reduces the risk of oocyst shedding and environmental contamination [8]. The public health message should emphasize evidence-based risk reduction rather than promoting the abandonment or avoidance of cats [8].

Diagnostic and Surveillance Workflow

The following Mermaid diagram illustrates a typical diagnostic and surveillance workflow for toxoplasmosis in a veterinary and public health context.

flowchart TD
    A[Clinical Suspicion in Cat], > B{Serological Testing}
    B, >|IgG+/IgM-| C[Latent Infection]
    B, >|IgG+/IgM+| D[Active or Recent Infection]
    B, >|IgG-/IgM-| E[No Evidence of Infection]
    D, > F{Confirm with PCR}
    F, >|Positive| G[Confirm Active Infection]
    F, >|Negative| H[Consider Other Diagnoses]
    C, > I[No Treatment Needed]
    G, > J[Treatment with Clindamycin]
    J, > K[Monitor Clinical Response]
    K, > L[Repeat Serology/PCR]
    L, > M[Resolution]
    L, > N[Persistent Infection]
    N, > J
    E, > O[Advise on Prevention]
    O, > P[Feed Cooked Food]
    O, > Q[Keep Cat Indoors]
    O, > R[Daily Litter Box Cleaning]

Seroprevalence Data in Selected Populations

The table below summarizes seroprevalence data from selected studies in cats and other animal populations.

Vaccine Development

The development of effective vaccines against T. gondii is a priority for both veterinary and public health. A recombinant GRA12 vaccine has demonstrated efficacy in reducing oocyst shedding in domestic cats [31]. An inactivated vaccine has been used to reduce toxoplasmosis-associated mortality in captive wildlife [32]. Advances in antigen discovery and mRNA vaccine technology are being explored under a One Health framework [35]. The goal is to develop vaccines that can prevent oocyst shedding in cats and reduce the risk of infection in intermediate hosts, including humans [35, 31].

Conclusion

Toxoplasmosis remains a significant zoonotic disease with complex transmission dynamics involving cats as definitive hosts and a wide range of intermediate hosts. The public health burden is considerable, particularly for immunocompromised individuals and congenitally infected neonates. Veterinary professionals play a critical role in diagnosing infection in cats, advising clients on prevention strategies, and contributing to surveillance efforts. Evidence-based public health messaging should focus on practical risk reduction measures, such as proper food handling and hygiene, rather than perpetuating stigmatizing stereotypes like "toxoplasmosis cat lady disease." Continued research into parasite biology, diagnostic tools, and vaccine development is essential for reducing the global impact of this parasite.

References

[1] Alrubaye HS, Reilly SM, da Silva R, et al. A single-cell atlas of Toxoplasma sexual development in the feline intestinal tract. Nat Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42020723/

[2] Alkhatatbeh SK, Lafi SQ, Hammad HB, et al. The first seroprevalence and molecular detection of toxoplasmosis infecting cats in Jordan with associated risk factors. Vet Parasitol Reg Stud Reports. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41741047/

[3] Muhammad AS, Kudi AC, Mohammed A, et al. Public health significance of prevalence and risk factors associated with Toxoplasma gondii infection in goats sampled from two quarantine facilities and an institutional farm in Maiduguri metropolis, Borno state, Nigeria. Sci Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42020619/

[4] Kołodziej-Sobocińska M, Holec-Gąsior L, Ferra B, et al. A long-term serological survey of Toxoplasma gondii in European bison (Bison bonasus) - the largest european herbivore. Vet Res Commun. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41359089/

[5] Mihaljević D, Sitaš Z, Hanulak J, et al. Cerebral Toxoplasmosis in a Renal Transplant Recipient-A Rare Complication. Life (Basel). 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41900989/

[6] Minani S, Di Bari C, Devleesschauwer B, et al. Assessing the burden of congenital toxoplasmosis in Burundi, 2020. Acta Trop. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40915592/

[7] Walana W, Odai SA, Tamomh AG. Prevalence, risk factors, diagnosis and outcomes of Toxoplasma gondii infection in pregnancy: A review. Parasitol Int. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/40818485/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

[8] Gharbi M, Yera H, Dupouy-Camet J. [The cat, the women and the toxoplasma: What advice should be given to a pregnant woman who is seronegative for toxoplasmosis and owns a cat?]. Gynecol Obstet Fertil Senol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41628830/

[9] Sena F, Hakimi M-A, Francia ME. Proliferating toward sex: characterization of cell division of Toxoplasma gondii's pre-sexual stages. mBio. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42153709/

[10] Spada E, Tattarletti G, Proverbio D, et al. The AB Blood Group System Phenotype Does Not Play a Role in Toxoplasma gondii Infection in Cats. Pathogens. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41471183/

[11] Kengradomkij C, Chimnoi W, Kamyingkird K, et al. PCR detection of Toxoplasma gondii DNA in fecal samples from stray cats in Bangkok Metropolitan, Thailand. Food Waterborne Parasitol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42094705/

[12] Bazan L, Argibay HD, Borges-Silva W, et al. Seroprevalence and risk factors for Toxoplasma gondii infection in wild, domestic and companion animals in urban informal settlements from Salvador, Brazil. PLoS Negl Trop Dis. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41401226/

[13] Schanz ML, Zhao F, Zadeii KE, et al. The cat's out of the bag: Toxoplasma gondii provides further insight into myeloid-mediated host defense. Immunohorizons. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40854593/

[14] Jesuthasan J, Merritt K, Solmi F, et al. The association between childhood Toxoplasma gondii, psychotic experiences and grey matter volume: A population-based cohort study. Schizophr Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41643571/

[15] Pielok Ł, Sałamatin R, Swarcewicz J, et al. Toxocarosis, toxoplasmosis and ocular dirofilariasis diagnosed in a polish farmer from Wielkopolska Voivodeship - a case description. BMC Ophthalmol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41225401/

[16] Cancela S, Sena F, Pagotto R, et al. Enhancing pre-sexual and sexual differentiation of Toxoplasma gondii using retinal epithelial cells and intestinal organoids. Cell Rep. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41108686/

[17] Khosravi S, Hajipour N, Moosavy MH, et al. Survival Rate of Toxoplasma gondii Tachyzoites in Cow's Milk at Different Temperatures. Vet Med Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40884309/

[18] Karacali B, Mor N. Investigation of anti-Toxoplasma gondii antibody seropositivity and possible risk factors in women with abortion or stillbirth history in Kars, Turkey. Afr J Reprod Health. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42202767/

[19] Tahita MC, Kaboré B, Ilboudo H, et al. Toxoplasma gondii seroprevalence and associated factors among pregnant women attending their first antennal care visit in rural Burkina Faso. J Parasit Dis. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40901422/

[20] Orish VN, Tetteh RE, Adzah D, et al. Toxoplasma gondii seropositivity among patients with sickle cell disease: Prevalence and association with blood transfusion history. PLoS One. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41931585/

[21] Elsohaby I, Zubair M, Baqar Z, et al. Seroprevalence of Toxoplasma gondii and associated demographic factors in privately-owned dogs, cats, and community cats in Hong Kong. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42135800/

[22] Lider LA, Kiyan V, Mannapova NE, et al. Seroprevalence of Toxoplasma gondii infection in urban client-owned cats in Kazakhstan. Vet Res Commun. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40875169/

[23] Fonseca J, Almeida P, Campos S, et al. Identification of a mouse-virulent recombinant type I/III Toxoplasma gondii strain in liver cytology of an immunosuppressed cat infected with FeLV-C subgroup. Vet Res Commun. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41108469/

[24] Günay-Esiyok Ö, Koçkaya ES, Yılmaz R, et al. The Potential of MIC17A both as an Entero-epithelial and Chronic Stage Marker for Detection of Feline Toxoplasmosis. Curr Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41874672/

[25] Askaryanzardak A, Kakkassery V, Tartaglione Gracia GP, et al. [Ocular toxoplasmosis in adults : Refresher course]. Ophthalmologie. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41603939/

[26] Roya SK, Maryam ER, Ahmad H, et al. Investigation of the Prevalence of Toxoplasmosis in Patients with Malignancies, Southwest of Iran. Arch Razi Inst. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41179623/

[27] Mu X, Chen C, Pu X, et al. Development and Field Validation of a Double-Antigen Sandwich Colloidal Gold Immunochromatographic Strip for Detection of Toxoplasma gondii Antibodies in Multiple Host Species. Transbound Emerg Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42253330/

[28] de Velasco-Reyes I, Torres-García SE, Hernández-Rangel JJ, et al. Seroprevalence of Toxoplasma gondii Infection in Veterinary Medicine Professionals and Students in Aguascalientes, Mexico. Epidemiologia (Basel). 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42201205/

[29] Chen XX, Sun H, Liang Y, et al. Development of a SAG1-based colloidal gold immunochromatographic strip for rapid serological detection of swine Toxoplasma gondii. Parasit Vectors. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42169035/

[30] Li YY, Bai SY, Yu HQ, et al. Development and evaluation of an antisense PCR assay for Toxoplasma gondii detection in domestic cats. Vet Parasitol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41724116/

[31] Yang J, Nie L, Song Y, et al. Immunogenicity and Protective Efficacy of a Recombinant Toxoplasma gondii GRA12 Vaccine in Domestic Cats. Vaccines (Basel). 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40872935/

[32] Scuotto A, Ogonczyk-Makowska D, Quiévy A, et al. Retrospective Analysis of the Impact of Vaccination with an Inactivated Vaccine on Toxoplasmosis-Associated Mortality in Captive Wildlife. Vaccines (Basel). 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41012115/

[33] Artiaga-Silva GL, de Lima Ruy Dias ÁF, Carvalho MR, et al. High Seroprevalence Rates of Toxoplasma gondii and Neospora caninum in Dogs in the Pantanal Region of Mato Grosso, Brazil. Acta Parasitol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41843222/

[34] Didkowska A, Kołodziej-Sobocińska M, Matusik K, et al. Toxoplasma gondii in wild felides in Poland. BMC Vet Res. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41387866/

[35] Qadeer A, Tharwat M, Khan MZ, et al. Advances and Translational Challenges in Toxoplasma gondii Vaccine Development: From Antigen Discovery to mRNA and One Health Strategies. Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42188907/